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For a�out �� years� the European School of Hema-
tology �ESH� and the European Hematology Associa-
tion �EHA� have cooperated in organizing educational 
activities in the field of continuous medical education 
designed in colla�oration with the international ex-
perts. ESH has worked much to improve and harmo-
nize the quality of education in hematology throughout 
Europe with the active implication of the world’s most 
prominent hematologists and hematology organiza-
tions. In ����� the Joint ESH-EHA Executive Commit-
tee was organized. The Committee mem�ers E. Gluck-
man and B. Lоwen�erg from ESH� W. Fi��e and R. Foa 
from EHA have developed a framework for continuing 
colla�oration in the field including the workshops and 
training courses for hematologists. Among the scien-
tific and educational courses on the latest develop-
ments in hematology� the hematology tutorials are 
of great interest for all those who are eager to improve 
and update their knowledge in various fields of modern 
hematology. 
The scientific program of the tutorials comprising 
plenary lectures� interactively conducted clinical case 
study sessions and self-assessment sessions is de-
signed to encourage interaction �etween the faculty 
and the course participants. For many years� within 
the framework of ESH-EHA program for continuous 
medical education� conferences� training courses and 
la�oratory workshops have �een organized in various 
countries throughout the world. The hematology tu-
torials involving a faculty of international experts are 
targeted to clinicians� �iologists and students working 
in the field of hematological malignancies. 
It was the first time when the hematology tutorial 
was held in Kyiv� Ukraine. The ��th Hematology Tutorial 
promoted a modern view of morphology� pathogen-
esis� diagnosis and treatment of lymphoid malig-
nancies. The faculty of this tutorial consisted of the 
leading experts from different countries: Prof. R. Foa 
and Prof. G. Gaidano from Italy. Prof. C. �earden from 
United Kingdom� Prof. S. McCann and Prof. E. Van-
den�erghe from Ireland� Prof. E. Kim�y from Sweden� 
Prof. �. Gluzman and Prof. I. Kriachok from Ukraine. 
Among the audience comprising a�out ��� people 
were clinicians and researchers specializing in hema-
tology arriving from various cities throughout Ukraine.
As a courtesy of ESH-ESA and personally of the 
faculty of the meeting� the lecturers have provided 
their permissions for pu�lishing the extended a�-
stracts of their lectures in this issue of Experimental 
Oncology.  
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Lymphoid malignancies are tumors of the immune 
system that originate from B or T lymphocytes and� rarely� 
from NK cells. They encompass extremely heterogeneous 
group of diseases �ased on their histological forms� 
�iologic and molecular genetic features� sites of clinical 
presentation �nodal or extranodal�� tumor �ehavior �local-
ized or disseminated�� and response to the treatment.
The history of recognition and classification of lym-
phoid malignancies is long� controversial and compli-
cated. Two classification systems have �een widely 
used until recently� the Kiel classification of non-Hodg-
kin’s lymphomas and the Working Formulation for clinical 
usage. In �99� after the immunologic revolution �creation 
the hy�ridoma technology that led to the development 
of monoclonal anti�odies� and dramatic progress in un-
derstanding the genetics of lymphoid malignancies�� 
the International Lymphoma Study Group �ILSG� of ex-
perienced hematologists formulated new proposals for 
a modern lymphoma classification� the so-called Revised 
European American Lymphoma �REAL� classification. 
With some additions and corrections� it has �een devel-
oped into World Health Organization ������ classification 
�E.S. Jaffe� N.L. Harris� H. Stein� J.W. Vardiman� eds. 
Pathology and Genetics of Tumours of Haematopoietic 
and Lymphoid Tissues. Lyon: IARC Press� ����. �5� p.�.
The �th edition of the WHO classification of Tumours 
of Haematopoietic and Lymphoid Tissues ������ incor-
porates new information that has emerged from �asic 
and clinical investigations and includes new defining 
criteria for some diseases as well as num�er of new 
entities defined �y a com�ination of immunopheno-
type� genetic criteria and clinical features.
The recent WHO classification ������ has �een 
updated as a joint effort of more than ��� hemopatho-
gists from �� countries. WHO classification of the B cell� 
T cell and NK cell neoplasms that in many respects re-
capitulate normal stage of lymphoid cell differentiation 
su�dividing tumors into those with an immature or �las-
tic appearance versus more mature stage of lymphoid 
development. This classification system represents 
a significant advance in our a�ility to understand� iden-
tify and treat different lymphoma entities. It is �ased 
on the concept of clinicopathologic entities in which 
histology� immunophenotype� molecular genetic data 
as well as clinical features are integrated. The putative 
cell origin and stage of differentiation of different types 
of lymphoid malignancies is also taken into account.
According to our experience� the application of im-
munocytochemical and molecular genetic studies has 
led to the detection of small num�er of pathologic cells 
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in peripheral �lood and �one marrow of some patients 
with non-Hodgkin’s lymphomas.
In �99�� the Reference La�oratory was set up as a pu�-
lic service on the �asis of the Immunocytochemistry 
�epartment of R.E. Kavetsky Institute of Experimental 
Pathology� Oncology and Radio�io logy� National Acad-
emy of Sciences of Ukraine with the aim of the precise 
diagnosis of the haematopoietic malignancies �ased 
on cytomorphology� cytoche mistry� immunophenotyping 
and the techniques of molecular �iology in accordance 
with FAB� WHO� EGIL� IC�-�� and IC�-O-� classifications. 
The diagnostic activity of the Reference La�oratory covers 
�5-�5% of all Ukrainian patients with acute leukemias� 
chronic lymphoid and myeloid leukemias� myelodysplastic 
syndromes� malignant lymphomas� histiocytosis� and 
metastatic lesions of lymph nodes and �one marrow. 
At present� the patients with tumors of haematopoietic and 
lymphoid tissues are diagnosed according to up-to-date 
WHO classification. We �elieve that only precise diagnosis 
of the major types of hematological malignancies to the 
up-to-date classification with delineation of the specific 
�iological su�types of hematological malignancies may 
represent the �asis for further molecular �iological and 
epidemiological studies. New insight into the �iology of the 
lymphoid malignancies in the coming years might well 
improve our a�ility to evaluate patients and chose therapy.
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Chronic lymphocytic leukemia �CLL� is the most com-
mon form of leukemia in Western countries with an inci-
dence of �.�/�������/year [�]. The incidence increases 
to >��/�������/year at an age of >�� years. The median 
age at diagnosis is �� years. A�out ��% of CLL patients 
are reported to �e younger than 55 years.
The guidelines for the diagnosis and treatment 
of chronic lymphocytic leukemia were revised �y the 
International Workshop on CLL in ���� �IWCLL�. Crite-
ria for CLL are as follows: the presence in the peripheral 
�lood of 5 x ��9/L monoclonal B lymphocytes for the 
at least � months. The clonality of the circulating B lym-
phocytes needs to �e confirmed �y flow cyto metry [�]. 
Typical immunophenotype of CLL lymphocyte is C�5+� 
C���+� C���+/-� C���-� C��9+� C��� dim� slgdim+ and 
cyclin �I� [�]. Bone marrow examination is not required 
for diagnosis and a CT scan not required for staging� 
�ut flow cytometry is crucial for correct diagnosis.
The first prognostic marker to �e used in the 
clinical management of CLL was the Rai clinical stag-
ing system� pu�lished in �9�5 [�]. This system was 
later followed �y the Binet staging system� pu�lished 
in �9�� [5]. Both of these staging systems provide 
a �asic framework for estimating prognosis and are 
factored into the current International Workshop 
on CLL guidelines for initiation of treatment [�].
Multiple factors� measured in standard clinical la�-
oratory tests� affect the clinical course of CLL. These 
factors include lymphocyte count� lymphocyte dou-
�ling time� M level� sTK level� angiopoietin-� �Ang-�� 
level� and solu�le cluster designation markers �C���� 
C���� and C��9d�. Other clinical markers that have 
�een investigated as potential prognostic indicators 
include age� gender [6]� lymphocyte dou�ling time [�]� 
num�er of prolymphocytes [�]� pattern of �one mar-
row involvement and percentage of smudge cells [9].
Approximately ��% of individuals with CLL have 
acquired chromosomal a�normalities within their 
malignant clone and can �e categorized into five 
prognostic groups accordingly: deletion ��q �median 
survival� ��� months�; deletion ��q �median survival� 
�9 months�; trisomy �� �median survival� ��� months�; 
normal cytogenetics �median survival� ��� months�; 
and deletion ��p �median survival� �� months�. Re-
ciprocal chromosome translocations are descri�ed 
�ut are rare in CLL. A complex cytogenetic karyotype 
can �e identified in ~I6% of patients and is commonly 
associated with poor prognostic features including 
C��� expression and unmutated IgHV [��].
The outcome of patients with leukemic cells that use 
an unmutated IgVH gene is inferior to those patients with 
leukemic cells that use a mutated IgVH gene. In addi-
tion� the VH�.�� gene usage is an unfavora�le prognos-
tic marker independent of the IgVH mutational status. 
Leukemic cell expression of ZAP-�� and C��� was 
found to correlate with the expression of unmutated 
IgVH genes and to predict a poor prognosis.
However� the association �etween expression of ZAP-
�� or C��� with the expression of unmutated IgVH genes 
is not a�solute. It is uncertain whether leukemia-cell 
expression of unmutated IgVH genes or ZAP-�� pre-
dict the response to treatment or overall survival� once 
therapy is required. Taken together� further clinical trials 
are needed to standardize the assessment of these pa-
